The Role and Therapeutic Potential of Melatonin in Degenerative Fundus Diseases: Diabetes Retinopathy and Age-Related Macular Degeneration
Chao Ma,Haoyu Li,Shuwen Lu,Xian Li
DOI: https://doi.org/10.2147/dddt.s471525
IF: 4.3188
2024-06-19
Drug Design Development and Therapy
Abstract:Chao Ma, 1, &ast Haoyu Li, 2, 3, &ast Shuwen Lu, 4 Xian Li 5, 6 1 Department of Ophthalmology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China; 2 Department of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; 3 Hunan Clinical Research Centre of Ophthalmic Disease, Changsha, Hunan, People's Republic of China; 4 Department of Ophthalmology, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, People's Republic of China; 5 Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, UK; 6 Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK &astThese authors contributed equally to this work Correspondence: Chao Ma, Department of Ophthalmology, the First Affiliated Hospital of Zhengzhou University, 1 Jianshe East Road, Zhengzhou, Henan, 450052, People's Republic of China, Tel +86-371-66278091, Email Degenerative fundus disease encompasses a spectrum of ocular diseases, including diabetic retinopathy (DR) and age-related macular degeneration (AMD), which are major contributors to visual impairment and blindness worldwide. The development and implementation of effective strategies for managing and preventing the onset and progression of these diseases are crucial for preserving patients' visual acuity. Melatonin, a neurohormone primarily produced by the pineal gland, exhibits properties such as circadian rhythm modulation, antioxidant activity, anti-inflammatory effects, and neuroprotection within the ocular environment. Furthermore, melatonin has been shown to suppress neovascularization and reduce vascular leakage, both of which are critical in the pathogenesis of degenerative fundus lesions. Consequently, melatonin emerges as a promising therapeutic candidate for degenerative ocular diseases. This review provides a comprehensive overview of melatonin synthesis, its localization within ocular tissues, and its mechanisms of action, particularly in regulating melatonin production, thereby underscoring its potential as a therapeutic agent for degenerative fundus diseases. Keywords: melatonin, fundus degeneration, oxidative stress, inflammation, anti-apoptotic Fundus degeneration encompasses a spectrum of ocular conditions, notably age-related macular degeneration (AMD) and diabetic retinopathy (DR). 1 In developed nations, AMD stands as the primary cause of legal blindness in individuals aged 60 and above, particularly among those of Caucasian descent. 2 Projections suggest that the number of diagnosed AMD cases will rise to 196 million by 2020 and 288 million by 2040. 3 The etiology of AMD is complex and not yet fully elucidated, although certain risk factors have been identified as potential contributors to the development of the condition. 4 Smoking and sunlight exposure are known to worsen environmental risk factors, with age being identified as the primary demographic risk factor. Additionally, research indicates that nutritional factors, gut microbiota, hypertension, and genetic variability play a role in the development of wet AMD. 5 Advanced wet AMD can lead to severe visual impairment due to choroidal neovascularization. 6 DR is associated with various microvascular complications, including blindness, particularly in individuals under the age of 40. 7 The estimated prevalence of diabetes is 400 million individuals, with one third experiencing DR and one tenth affected by vision-threatening conditions such as diabetic macular edema and proliferative DR (PDR). 8 Worldwide, DR and AMD are the major causes of vision impairment and blindness. 9 Given the increasing prevalence of diabetes and aging populations, the prevention and treatment of fundus degenerative diseases are of heightened importance. Melatonin, a neurohormone predominantly produced by the pineal gland, has been the subject of extensive research and application across various disciplines. 10 Eye research has particularly focused on the interaction between melatonin and the eyes, especially retinal ganglion cells. Additionally, studies have explored the impact of eye lesions on the circadian rhythm regulation of melatonin. 11 Besides its role in regulating circadian rhythms, melatonin serves crucial physiological functions in ocular structures. Evidence suggests that a deficiency in melatonin may contribute to the development of AMD, as indicated by reduced melatonin production in AMD patients compare -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal